ReposiTrak (NYSE:TRAK) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of ReposiTrak (NYSE:TRAK) from a hold rating to a buy rating in a report released on Saturday.

Separately, Weiss Ratings restated a “hold (c+)” rating on shares of ReposiTrak in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock has an average rating of “Hold”.

ReposiTrak Stock Performance

Shares of ReposiTrak stock opened at $11.81 on Friday. The stock has a market cap of $216.00 million, a P/E ratio of 32.81 and a beta of 0.41. The stock’s fifty day moving average is $13.81 and its 200 day moving average is $15.98. ReposiTrak has a one year low of $11.79 and a one year high of $23.72.

ReposiTrak (NYSE:TRAK) last issued its quarterly earnings results on Thursday, November 13th. The company reported $0.09 EPS for the quarter. ReposiTrak had a return on equity of 14.37% and a net margin of 30.52%.The business had revenue of $5.97 million during the quarter.

Insider Activity

In other ReposiTrak news, CEO Randall K. Fields sold 7,500 shares of the stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $12.34, for a total transaction of $92,550.00. Following the completion of the sale, the chief executive officer directly owned 160,000 shares of the company’s stock, valued at $1,974,400. This trade represents a 4.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ronald C. Hodge sold 18,906 shares of ReposiTrak stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $13.16, for a total transaction of $248,802.96. Following the sale, the director owned 561,869 shares in the company, valued at approximately $7,394,196.04. The trade was a 3.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 110,547 shares of company stock valued at $1,532,070 in the last quarter. 41.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ReposiTrak

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its stake in ReposiTrak by 63.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,633 shares of the company’s stock worth $32,000 after purchasing an additional 634 shares in the last quarter. Copeland Capital Management LLC bought a new stake in shares of ReposiTrak in the third quarter worth about $54,000. Tower Research Capital LLC TRC lifted its position in shares of ReposiTrak by 397.3% in the second quarter. Tower Research Capital LLC TRC now owns 3,620 shares of the company’s stock worth $71,000 after buying an additional 2,892 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of ReposiTrak in the third quarter worth about $219,000. Finally, R Squared Ltd purchased a new position in ReposiTrak during the 2nd quarter valued at approximately $235,000. 27.35% of the stock is owned by hedge funds and other institutional investors.

About ReposiTrak

ReposiTrak, trading on the New York Stock Exchange under the symbol TRAK, is a provider of cloud-based supply chain compliance and transparency solutions. The company’s platform enables retailers, suppliers and manufacturers to manage, share and validate product data throughout the supply chain. Through its Software-as-a-Service (SaaS) offering, ReposiTrak helps organizations ensure adherence to regulatory requirements, industry standards and retailer-specific guidelines for food safety, sustainability, labeling and quality assurance.

At the core of ReposiTrak’s offerings is its DataHub, a centralized repository that captures critical information such as product specifications, certifications, catch-weight data, temperature logs and recall notifications.